Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 5, 2016, Pages 1102-1116

  Baldo, Aline ^a   Galanis, Evanthia ^b   Tangy, Frédéric ^c   Herman, Philippe ^a  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b MAYO CLINIC   (United States)

^c CNRS   (France)

Author keywords

biosafety; measles virus (MV); MV Edmonston strains; vaccination; viral vectors; virotherapy

Indexed keywords

MEASLES VACCINE; MEMBRANE COFACTOR PROTEIN; ONCOLYTIC VIRUS; VIRUS VECTOR; LIVE VACCINE;

BREAST CANCER; CLINICAL TRIAL (TOPIC); GENETIC STABILITY; GLIOBLASTOMA; HUMAN; MEASLES VIRUS; MULTIPLE MYELOMA; MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; REVIEW; TRANSGENE; VACCINATION; VIROTHERAPY; VIRUS ATTENUATION; VIRUS SHEDDING; ANIMAL; GENE VECTOR; GENETICS; HAZARDOUS WASTE; IMMUNOLOGY; MEASLES; METABOLISM; MOUSE; ONCOLYTIC VIROTHERAPY; PHYSIOLOGY; PROCEDURES; VIRUS ENTRY;

ANIMALS; ANTIGENS, CD46; CONTAINMENT OF BIOHAZARDS; GENETIC VECTORS; HUMANS; MEASLES; MEASLES VACCINE; MEASLES VIRUS; MICE; ONCOLYTIC VIROTHERAPY; VACCINATION; VACCINES, ATTENUATED; VIRUS INTERNALIZATION;

EID: 84961390705     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1122146     Document Type: Review

References (123)

1. X.Zhang, L.J.Rennick, W.P.Duprex, B.K.Rima. Determination of spontaneous mutation frequencies in measles virus under nonselective conditions. J Virol 2013; 87:2686-92; PMID:23255805; http://dx.doi.org/10.1128/JVI.02146-12
2. M.A.Billeter, H.Y.Naim, S.A.Udem. Reverse genetics of measles virus and resulting multivalent recombinant vaccines: applications of recombinant measles viruses. Curr Top Microbiol Immunol 2009; 329:129-62; PMID:19198565
3. J.F.Enders, T.C.Peebles. Propagation in tissue cultures of cytopathogenic agents from patients with measles. Proc Soc Exp Biol Med 1954; 86:277-86; PMID:13177653; http://dx.doi.org/10.3181/00379727-86-21073
4. J.F.Enders, S.L.Katz, M.V.Milovanovic, A.Holloway. Studies on an attenuated measles-virus vaccine. I. Development and preparations of the vaccine: technics for assay of effects of vaccination. N Engl J Med 1960; 263:153-9; PMID:13820246; http://dx.doi.org/10.1056/NEJM196007282630401
5. B.Bankamp, M.Takeda, Y.Zhang, W.Xu, P.A.Rota. Genetic characterization of measles vaccine strains. J Infect Dis 2011; 204 (Suppl 1):S533-48; PMID:21666210; http://dx.doi.org/10.1093/infdis/jir097
6. C.Erlenhöfer, W.P.Duprex, B.K.Rima, V.ter Meulen, J.Schneider-Schaulies. Analysis of receptor (CD46, CD150) usage by measles virus. J Gen Virol 2002; 83:1431-6; PMID:12029158; http://dx.doi.org/10.1099/0022-1317-83-6-1431
7. Y.Yanagi, N.Ono, H.Tatsuo, K.Hashimoto, H.Minagawa. Measles virus receptor SLAM (CD150). Virology 2002; 299:155-61; PMID:12202217; http://dx.doi.org/10.1006/viro.2002.1471
8. A.Zuniga, Z.Wang, M.Liniger, L.Hangartner, M.Caballero, J.Pavlovic, P.Wild, J.F.Viret, R.Glueck, M.A.Billeter, et al. Attenuated measles virus as a vaccine vector. Vaccine 2007; 25:2974-83; PMID:17303293; http://dx.doi.org/10.1016/j.vaccine.2007.01.064
9. D.Ikic, M.Juzbasic, M.Beck, A.Hrabar, T.Cimbur-Schreiber. Attenuation and characterisation of Edmonston-Zagreb measles virus. Ann Immunol Hung 1972; 16:175-81; PMID:4679646
10. D.Ikic Edmonston-Zagreb strain of measles vaccine: epidemiologic evaluation in Yugoslavia. Rev Infect Dis 1983; 5:558-63; PMID:6879014; http://dx.doi.org/10.1093/clinids/5.3.558
11. M.Beck, S.Smerdel, I.Dedic, N.Delimar, M.Rajninger-Miholic, M.Juzbasic, T.Manhalter, R.Vlatkovic, B.Borcic, Z.Mihajic. Immune response to Edmonston-Zagreb measles virus strain in monovalent and combined MMR vaccine. Dev Biol Stand 1986; 65:95-100; PMID:3556780
12. D.L.Bolton, S.Santra, C.Sweet, J.Custers, K.Song, H.Balachandran, P.A.Kozlowski, N.Letvin, M.Roeder, K.Radosevic. Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates. Vaccine 2012; 30:5991-98; PMID:22732429; http://dx.doi.org/10.1016/j.vaccine.2012.06.029
13. T.Mori, K.Sasaki, H.Hashimoto, S.Makino. Molecular cloning and complete nucleotide sequence of genomic RNA of the AIC-K strain of attenuated measles virus. Virus Genes 1993; 7:67-81; PMID:8470368; http://dx.doi.org/10.1007/BF01702349
14. H.Mirchamsy, A.Shafyi, S.Bahrami, M.Kamali, P.Nazari. Use of human diploid cell MRC-5 for production of measles and rubella virus vaccines. Dev Biol Stand 1976; 37:297-300; PMID:1031692
15. S.Makino Development and characteristics of live AIC-K measles virus vaccine: a brief report. Rev Infect Dis 1983; 5:504-5; PMID:6410489; http://dx.doi.org/10.1093/clinids/5.3.504
16. A.Zuniga, M.Liniger, T.N.Morin, R.R.Marty, M.Wiegand, O.Ilter, S.Weibel, M.A.Billeter, M.C.Knuchel, H.Y.Naim. Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector. Hum Vaccin Immunother 2013; 9:607-13; PMID:23324616; http://dx.doi.org/10.4161/hv.23242
17. WHO position on measles vaccines. Vaccine 2009; 27:7219-21; PMID:19833246; http://dx.doi.org/10.1016/j.vaccine.2009.09.116
18. S.Brandler, F.Tangy. Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines. Comp Immunol Microbiol Infect Dis 2008; 31:271-91; PMID:17869338; http://dx.doi.org/10.1016/j.cimid.2007.07.012
19. N.Escriou, B.Callendret, V.Lorin, C.Combredet, P.Marianneau, M.Février, F.Tangy. Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein. Virology 2014; 452-453:32-41
20. C.Lorin, L.Segal, J.Mols, J.Morelle, P.Bourguignon, O.Rovira, P.Mettens, J.Silvano, N.Dumey, F.Le Goff, et al. Toxicology, biodistribution and shedding profile of a recombinant measles vaccine vector expressing HIV-1 antigens, in cynomolgus macaques. Naunyn Schmiedebergs Arch Pharmacol 2012; 385:1211-25; PMID:22983013; http://dx.doi.org/10.1007/s00210-012-0793-4
21. P.Msaouel, A.Dispenzieri, E.Galanis. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther 2009; 11:43-53; PMID:19169959
22. M.D.Mühlebach, M.Mateo, P.L.Sinn, S.Prüfer, K.M.Uhlig, V.H.Leonard, C.K.Navaratnarajah, M.Frenzke, X.X.Wong, B.Sawatsky, et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 2011; 480:530-3; PMID:22048310
23. R.S.Noyce, C.D.Richardson. Nectin 4 is the epithelial cell receptor for measles virus. Trends Microbiol 2012; 20:429-39; PMID:22721863; http://dx.doi.org/10.1016/j.tim.2012.05.006
24. P.Msaouel, M.Opyrchal, M.E.Domingo, E.Galanis. Oncolytic measles virus strains as novel anticancer agents. Expert Opin Biol Ther 2013; 13:483-502; PMID:23289598; http://dx.doi.org/10.1517/14712598.2013.749851
25. U.S. National Institutes of Health. ClinicalTrials.gov [Internet]. Study to Evaluate the Dosage and Safety of Two Intramuscular Injections of an Investigational Clade B HIV Vaccine. Official title: An open-label, Phase I, Dose-escalation and safety study of two intramuscular injections of a Dose of 2.9 Log or 4 Log CCID50 of the Recombinant HIV I clade B Measles Vaccine Vector in Healthy Adults. ClinicalTrials.gov Identifier, NCT01320176; 2011 Mar 21 [updated 2012 Feb 13; cited 2016 Jan 26]. Availaible from: http://clinicaltrials.gov/ct2/show/NCT01320176
26. K.Ramsauer, M.Schwameis, C.Firbas, M.Müllner, R.J.Putnak, S.J.Thomas, P.Desprès, E.Tauber, B.Jilma, F.Tangy. Immunogenicity, safety and tolerability of a recombinant measles virus-based chikungunya vaccine: an observer and subject blinded, block randomised, active and placebo-controlled first in man trial. Lancet Infect Dis 2015; 15:519-527; PMID:25739878; http://dx.doi.org/10.1016/S1473-3099(15)70043-5
27. E.Galanis, L.C.Hartmann, W.A.Cliby, H.J.Long, P.P.Peethambaram, B.A.Barrette, J.S.Kaur, P.J.HaluskaJr, I.Aderca, P.J.Zollman, et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 2010; 70:875-82; PMID:20103634; http://dx.doi.org/10.1158/0008-5472.CAN-09-2762
28. E.Galanis, P.J.Atherton, M.J.Maurer, K.L.Knutson, S.C.Dowdy, W.A.Cliby, P.J.HaluskaJr, H.J.Long, A.Oberg, I.Aderca, et al. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res 2015; 75:22-30; PMID:25398436; http://dx.doi.org/10.1158/0008-5472.CAN-14-2533
29. S.J.Russell, M.J.Federspiel, K.W.Peng, C.Tong, D.Dingli, W.G.Morice, V.Lowe, M.K.O'Connor, R.A.Kyle, N.Leung, et al. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin Proc 2014; 89:926-33; PMID:24835528; http://dx.doi.org/10.1016/j.mayocp.2014.04.003
30. Directive 2009/41/EC of the European Parliament and of the Council of 6 May 2009 on the contained use of genetically modified micro-organisms (Recast). Off J 21.05.2009; L 125:0075
31. Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the environment of genetically modified organisms and repealing Council Directive 90/220/EEC. Off J 17.04.2001; L106:1
32. Regulation (EC) No. 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Off J 30.04.2004; L 136:1
33. A.Baldo, E.van den Akker, H.E.Bergmans, F.Lim, K.Pauwels. General Considerations on the Biosafety of Virus-derived Vectors Used in Gene Therapy and Vaccination. Curr Gene Ther 2013; 13:385-94; PMID:24195604; http://dx.doi.org/10.2174/15665232113136660005
34. D.Griffin. Measles Virus. In: D.Knipe, P.Howley, eds. Field's virology. 4th ed. Philadelphia, Lippincott-Raven publishers, 2001: pp. 1401-41.
35. Y.Yanagi, M.Takeda, S.Ohno. Measles virus: cellular receptors, tropism and pathogenesis. J Gen Virol 2006; 87:2767-79; PMID:16963735; http://dx.doi.org/10.1099/vir.0.82221-0
36. R.D.de Vries, A.W.Mesman, T.B.Geijtenbeek, W.P.Duprex, R.L.de Swart. The pathogenesis of measles. Curr Opin Virol 2012; 2:248-55; PMID:22483507; http://dx.doi.org/10.1016/j.coviro.2012.03.005
37. L.de Witte, R.D.de Vries, M.van der Vlist, S.Yüksel, M.Litjens, R.L.de Swart, T.B.Geitenbeek. DC-SIGN and CD150 have distinct roles in transmission of measles virus from dendritic cells to T-lymphocytes. PLoS Pathog 2008; 4(4):e1000049; PMID:18421379; http://dx.doi.org/10.1371/journal.ppat.1000049
38. A.B.Bloch, W.A.Orenstein, W.M.Ewing, W.H.Spain, G.F.Mallison, K.L.Herrmann, A.R.Hinman. Measles outbreak in a pediatric practice: airborne transmission in an office setting. Pediatrics 1985; 75:676-83; PMID:3982900
39. R.M.Anderson, R.M.May. infectious diseases of humans. Dynamics and control. 11th ed. 2006.
40. D.E.Griffin, C.H.Pan, M.J.Moss. Measles vaccine. Front Biosci 2008; 13:1352-70; PMID:17981635; http://dx.doi.org/10.2741/2767
41. Public Health Agency of Canada [Internet]. Laboratory Biosafety and Biosecurity. Pathogen Safety Data Sheets and Risk Assessment - Measles virus; [updated 2011 Sep 08; cited 2016 Jan 26]. Available from: http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/measles-rougeole-eng.php
42. Atkinson W, Wolfe S, Hamborsky J, McIntyre L. Epidemiology and prevention of vaccine-preventable diseases. 11th ed. Washington (DC): Public Health Foundation; 2009.
43. World Health Organization. Laboratory Biosafety Manual. 3rd ed. Geneva; 2004, 178p. [online] Available from: http://www.who.int/csr/resources/publications/biosafety/Biosafety7.pdf?ua=1 Access date 26-01-2016.
44. Belgium Biosafety Server [Internet]. Belgian classifications for micro-organisms based on their biological risks - Definitions; 2006 Feb 28 [cited 2016 Jan 26]. Available from: http://www.biosafety.be/RA/Class/ClassBELdef.html
45. Directive 2000/54/EC of the European Parliament and of the Council of 18 September 2000 on the protection of workers from risks related to exposure to biological agents at work. Official Journal of the European Communities. 17.10.2000. L262/21.
46. D.Naniche, G.Varior-Krishnan, F.Cervoni, T.F.Wild, B.Rossi, C.Rabourdin-Combe, D.Gerlier. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol 1993; 67:6025-32; PMID:8371352
47. B.D.Anderson, T.Nakamura, S.J.Russell, K.W.Peng. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 2004; 64:4919-26; PMID:15256464; http://dx.doi.org/10.1158/0008-5472.CAN-04-0884
48. R.D.de Vries, K.Lemon, M.Ludlow, S.McQuaid, S.Yüksel, G.van Amerongen, L.J.Rennick, B.K.Rima, A.D.Osterhaus, R.L.de Swart, et al. In vivo tropism of attenuated and pathogenic measles virus expressing green fluorescent protein in macaques. J Virol 2010; 84:4714-24; PMID:20181691; http://dx.doi.org/10.1128/JVI.02633-09
49. J.Schnorr, L.Dunster, J.Nanan, J.Schneider-Schaulies, S.Schneider Schaulies, V.ter Meulen. Measles virus-induced down-regulation of CD46 is associated with enhanced sensitivity to complement-mediated lysis of infected cells. Eur J Immunol 1995; 25:976-984; PMID:7737301; http://dx.doi.org/10.1002/eji.1830250418
50. R.S.Noyce, D.G.Bondre, M.N.Ha, L.-T.Lin, G.Sisson, M.-S.Tsao, C.D.Richardson. Tumor cell marker PVRL4 (Nectin 4) is an epithelial cell receptor for measles virus. PloS Pathog 2011; 7:e1002240; PMID:21901103; http://dx.doi.org/10.1371/journal.ppat.1002240
51. F.Radecke, P.Spielhofer, H.Schneider, K.Kaelin, M.Huber, C.Dötsch, G.Christiansen, M.A.Billeter. Rescue of measles viruses from cloned DNA. EMBO J 1995; 14:5773-84; PMID:8846771
52. A.Zuniga, Z.Wang, M.Liniger, L.Hangartner, M.Caballero, J.Pavlovic, P.Wild, J.F.Viret, R.Glueck, M.A.Billeter, H.Y.Naim. Attenuated measles virus as a vaccine vector. Vaccine 2007; 25:2974-83; PMID:17303293; http://dx.doi.org/10.1016/j.vaccine.2007.01.064
53. U.S. National Institutes of Health. ClinicalTrials.gov [Internet]. Recombinant Measles Virus Vaccine Therapy and Oncolytic virus therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer. Official title: Phase I Trial of Intraperitoneal Administration of a) a CEA-Expressing Derivative, and b) a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer. ClinicalTrials.gov Identifier, NCT00408590; 2006 Dec 6 [updated 2015 Mar 23; cited 2016 Jan 26]. Available from: http://clinicaltrials.gov/ct2/show/NCT00408590
54. U.S. National Institutes of Health. ClinicalTrials.gov [Internet]. MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer. Official title: Phase I/II trial of intraperitoneal administration of adipose tissue derived mesenchymal stem cells infected with a NIS-expressing derivative manufactured from a genetically engineered strain of Measles virus in patients with recurrent ovarian cancer. ClinicalTrials.gov Identifier, NCT02068794; 2014 Feb 19 [updated 2015 Nov 16; cited 2016 Janv 26]. Available from: http://clinicaltrials.gov/ct2/show/NCT02068794
55. U.S. National Institutes of Health. ClinicalTrials.gov [Internet]. Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme. Official title: Phase I trial of Measles virus derivative producing CEA (MV-CEA) in patients with recurrent Glioblastoma Multiforme (GBM). ClinicalTrials.gov Identifier, NCT00390299; 2006 Oct 18 [updated 2015 oct 19; cited 2016 Jan 26]. Available from: http://clinicaltrials.gov/ct2/show/NCT00390299
56. U.S. National Institutes of Health. ClinicalTrials.gov [Internet]. Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma. Official title: Phase I Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, With or Without Cyclophosphamide, in Patients With Recurrent or Refractory Multiple Myeloma. ClinicalTrials.gov Identifier, NCT00450814; 2007 Mar 20 [updated 2015 Jul 25; cited 2016 Jan 26]. Available from: http://clinicaltrials.gov/ct2/show/NCT00450814
57. U.S. National Institutes of Health. ClinicalTrials.gov [Internet]. UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus. Official title: A phase II trial of oncolytic virotherapy by systemic administration of Edmonston strain of Measles virus, genetically engineered to express NIS, with cyclophosphamide, in patients with recurrent of refractory multiple myeloma. ClinicalTrials.gov Identifier, NCT02192775; 2014 Jul 2 [updated 2015 Sep 23; cited 2016 Jan 26]. Available from: http://clinicaltrials.gov/ct2/show/NCT02192775
58. U.S. National Institutes of Health. ClinicalTrials.gov [Internet]. Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma. Official title: A phase I Trial of oncolytic Measles virotherapy in Mesothelioma. ClinicalTrials.gov Identifier, NCT01503177; 2011 Dec 16 [updated 2016 Jan 7; cited 2016 Jan 26]. Available from: http://clinicaltrials.gov/ct2/show/NCT01503177
59. U.S. National Institutes of Health. ClinicalTrials.gov [Internet]. Viral Therapy in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer. Official title: Phase I Trial of intratumoral administration of a NIS-expressing derivative manufactured from a genetically engineered strain of Measles virus in patients with recurrent/metastatic squamous cell carcinoma of Head and Neck. ClinicalTrials.gov Identifier, NCT01846091; 2013 May 1 [updated 2016 Jan 4; cited 2016 Jan 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT01846091
60. J.B.Guillerme, M.Gregoire, F.Tangy, J.F.Fonteneau. Antitumor Virotherapy by Attenuated Measles Virus (MV). Biology 2013; 2:587-602; PMID:24832799; http://dx.doi.org/10.3390/biology2020587
61. E.van den Akker, C.J.van der Vlugt, D.A.Bleijs, H.E.Bergmans. Environmental risk assessment of replication competent viral vectors applied in clinical trials: potential effects of inserted sequences. Curr Gene Ther 2013; 13:395-412; PMID:24397527; http://dx.doi.org/10.2174/156652321306140103221621
62. M.Liniger, A.Zuniga, T.M.Morin, D.Combardiere, R.Marty, M.Wiegand, O.Iter, M.Knuchel, H.Y.Naim. Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral responses. Vaccine 2009; 27:3299-305; PMID:19200842; http://dx.doi.org/10.1016/j.vaccine.2009.01.057
63. P.Despres, C.Combredet, M.P.Frenkiel, C.Lorin, M.Brahic, F.Tangy. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J Infect Dis 2005; 191:207-14; PMID:15609230; http://dx.doi.org/10.1086/426824
64. S.Brandler, P.Marianneau, P.Loth, S.Lacôte, C.Combredet, M.-P.Frenkiel, P.Desprès, H.Contamin, F.Tangy. Measles vaccine expressing the secreted form of West Nile virus envelope glycoprotein induces protective immunity in squirrel monkeys, a new model of West Nile virus infection. J Infect Dis 2012; 206:212-9; PMID:22551814; http://dx.doi.org/10.1093/infdis/jis328
65. M.Yoneda, M.C.Georges-Courbot, F.Ikeda, M.Ishii, N.Nagata, F.Jacquot, H.Raoul, H.Sato, C.Kai. Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge. PLoS One 2013; 8:e58414; PMID:23516477; http://dx.doi.org/10.1371/journal.pone.0058414
66. S.Brandler, C.Ruffie, V.Najburg, M.-P.Frenkiel, H.Bedouelle, P.Desprès, F.Tangy. Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses. Vaccine 2010; 28:6730-9; PMID:20688034; http://dx.doi.org/10.1016/j.vaccine.2010.07.073
67. J.R.del Valle, P.Devaux, G.Hodge, N.J.Wegner, M.B.McChesney, R.Cattaneo. A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge. J Virol 2007; 81:10597-605; PMID:17634218; http://dx.doi.org/10.1128/JVI.00923-07
68. Y.Yamaji, T.Nakayama. Recombinant measles viruses expressing respiratory syncytial virus proteins induced virus-specific CTL responses in cotton rats. Vaccine 2014; 32:4529-36; PMID:24951869; http://dx.doi.org/10.1016/j.vaccine.2014.06.024
69. G.Cantarella, M.Liniger, A.Zuniga, J.T.Schiller, M.Billeter, H.Y.Naim, R.Glueck. Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma. Vaccine 2009; 27:3385-90; PMID:19200837; http://dx.doi.org/10.1016/j.vaccine.2009.01.061
70. D.E.Griffin, C.H.Pan. Measles: old vaccines, new vaccines. Curr Top Microbiol Immunol 2009; 330:191-212; PMID:19203111
71. H.Mawhinney, I.V.Allen, J.M.Beare, J.M.Bridges, J.H.Connolly, M.Haire, N.C.Nevin, D.W.Neill, J.R.Hobbs. Dysgammaglobulinaemia complicated by disseminated measles. Br Med J 1971; 2:380-1; PMID:5575976; http://dx.doi.org/10.1136/bmj.2.5758.380
72. A.Mitus, A.Holloway, A.E.Evans, J.F.Enders. Attenuated measles vaccine in children with acute leukemia. Am J Dis Child 1962; 103:413-8; PMID:14474744
73. W.J.Monafo, D.B.Haslam, R.L.Roberts, S.R.Zaki, W.J.Bellini, C.M.Coffin. Disseminated measles infection after vaccination in a child with a congenital immunodeficiency. J Pediatr 1994; 124:273-6; PMID:8301437; http://dx.doi.org/10.1016/S0022-3476(94)70318-3
74. W.J.Moss, C.J.Clements, N.A.Halsey. Immunization of children at risk of infection with human immunodeficiendy virus. Bulletin World Health Organization 2003; 81:61-70; PMID:12640478
75. J.B.Angel, P.Walpita, R.A.Lerch, M.S.Sidhu, M.Masurekar, R.A.DeLellis, J.T.Noble, D.R.Syndman, S.A.Udem. Vaccine-associated measles pneumonitis in an adult with AIDS. Ann Intern Med 1998; 192:104-106; PMID:NOT_FOUND; http://dx.doi.org/10.7326/0003-4819-129-2-199807150-00007
76. P.Aaby, K.Knudsen, H.Whittle, I.M.Lisse, J.Thaarup, A.Poulsen, M.Sodemann, M.Jakobsen, K.Brink, U.Gansted, et al. Long-term survival after Edmonston-Zagreb measles vaccination: Increased female mortality. J Pediatr 1993; 122:904-908; PMID:8501567; http://dx.doi.org/10.1016/S0022-3476(09)90015-4
77. P.Aaby, B.Samb, F.Simondon, K.Knudsen, A.M.Seck, J.Bennett, L.Markowitz, P.Rhodes, H.Whittle. Sex specific mortality after high titre measles vaccines in rural Senegal. Bull World Health Organ 1994; 72:761-70; PMID:7955026
78. Halsey. Increased mortality following high titre measles vaccines: Too much of a good thing. Pediatr Infect Dis J 1993; 12:462-465; PMID:8345977; http://dx.doi.org/10.1097/00006454-199306000-00002
79. National Institute of Health (NIH). National Institute of Allergy and Infectious Diseases (NIAID). The Jordan Report 2000: Accelerated Development of Vaccines.
80. G.D.Hussey, E.A.Goddard, J.Hugues, J.J.Ryon, M.Kerran, E.Carelse, P.M.Strebel, L.E.Markowitz, J.Moodie, P.Barron, et al. The effect of Edmonston-Zagreb and Schwarz measles vaccine on immune responses in infants. J Infect Dis 1996; 173:1320-1326; PMID:8648203; http://dx.doi.org/10.1093/infdis/173.6.1320
81. P.Aaby, H.Jensen, F.Simondon, H.Whittle. High-titer measles vaccination before 9 months of age and increased female mortality: do we have an explanation? Semin Pediat Infect Dis 2003; 14:220-232; PMID:NOT_FOUND; http://dx.doi.org/10.1016/S1045-1870(03)00037-2
82. S.L.Katz. Immunization with live attenuated measles virus vaccines: five years'experience. Arch Gesamte Virusforsch 1965; 16, 222-30; PMID:14322868; http://dx.doi.org/10.1007/BF01253813
83. S.Brandler, C.Ruffié, C.Combredet, J.-B.Brault, V.Najburg, M.-C.Prevost, A.Habel, E.Tauber, P.Desprès, F.Tangy. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Vaccine 2013; 31:3718-25; PMID:23742993; http://dx.doi.org/10.1016/j.vaccine.2013.05.086
84. R.Stebbings, M.Février, B.Li, C.Lorin, M.Koutsoukos, E.Mee, N.Rose, J.Hall, M.Page, N.Almond, G.Voss, F.Tangy. Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine. PLoS One 2012; 7(11):e50397; PMID:23226275; http://dx.doi.org/10.1371/journal.pone.0050397
85. R.Stebbings, B.Li, C.Lorin, M.Koutsoukos, M.Février, E.T.Mee, M.Page, N.Almond, F.Tangy, G.Voss. Immunogenicity of a recombinant measles HIV-1 subtype C vaccine. Vaccine 2013; 31:6079-86; PMID:24161574; http://dx.doi.org/10.1016/j.vaccine.2013.09.072
86. M.Guerbois, A.Moris, C.Combredet, V.Najburg, C.Ruffié, M.Février. Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160ΔV1V2 is strongly immunogenic. Virology 2009; 388:191-203; PMID:19345390; http://dx.doi.org/10.1016/j.virol.2009.02.047
87. + T cells in subjects seronegative or highly seropositive for measles vaccine. Clin Diagn Lab Immunol 2003; 10:411-6; PMID:12738640
88. E.Van Braeckel, P.Bourguignon, M.Koutsoukos, F.Clement, M.Janssens, I.Carletti, A.Collard, M.A.Demoitié, G.Voss, G.Leroux-Roels, et al. An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers. Clin Infect Dis 2011; 52:522-31; PMID:21208909; http://dx.doi.org/10.1093/cid/ciq160
89. M.D.Miller, M.B.Feinberg, W.C.Greene. The HIV-1 nef gene acts as a positive viral infectivity factor. Trends Microbiol 1994; 2:294-8; PMID:7981973; http://dx.doi.org/10.1016/0966-842X(94)90007-8
90. U.S. National Institutes of Health. ClinicalTrials.gov [Internet]. Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers. Official title: Dose-ranging Study to Compare the Safety and Immunogenicity of a Candidate HIV Vaccine 732461, Adjuvanted or Not, Administered According to a 0, 1 Month Schedule to Healthy Adult HIV Seronegative Volunteers. ClinicalTrials.gov Identifier, NCT00434512; 2007 Fev 12 [updated 2011 Oct 27; cited 2016 Jan 26] Available from: http://clinicaltrials.gov/ct2/show/NCT00434512
91. W.Akahata, Z.Y.Yang, H.Andersen, S.Sun, H.A.Holdaway, W.P.Kong, M.G.Lewis, S.Higgs, M.G.Rossmann, S.Rao, et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med 2010; 16:334-338; PMID:20111039; http://dx.doi.org/10.1038/nm.2105
92. L.-J.Chang, K.A.Dowd, F.H.Mendoza, J.G.Saunders, S.Sitar, S.H.Plummer, G.Yamshchikov, U.N.Sarwar, Z.Hu, M.E.Enama, et al. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation. Lancet 2014; 384:2046-2052; PMID:25132507; http://dx.doi.org/10.1016/S0140-6736(14)61185-5
93. C.Combredet, V.Labrousse, L.Mollet, C.Lorin, F.Delebecque, B.Hurtrel, H.McClure, M.B.Feinberg, M.Brahic, F.Tangy. A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J Virol 2003; 77:11546-54; PMID:14557640; http://dx.doi.org/10.1128/JVI.77.21.11546-11554.2003
94. R.M.Myers, S.M.Greiner, M.E.Harvey, G.Griesmann, M.J.Kuffel, S.A.Buhrow, J.M.Reid, M.Federspiel, M.M.Ames, D.Dingli, et al. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther 2007; 82:700-10; PMID:17971816; http://dx.doi.org/10.1038/sj.clpt.6100409
95. H.Bergmans, C.Logie, K.Van Maanen, H.Hermsen, M.Meredyth, C.Van der Vlugt. Identification of potentially hazardous human gene products in GMO risk assessment. Env Biosafety Res 2008; 7:1-9; PMID:18384725; http://dx.doi.org/10.1051/ebr:2008001
96. L.K.Hallak, J.R.Merchan, C.M.Storgard, J.C.Loftus, S.J.Russel. Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression. Cancer Res 2005; 65:5292-300; PMID:15958576; http://dx.doi.org/10.1158/0008-5472.CAN-04-2879
97. T.Nakamura, K.W.Peng, M.Harvey, S.Greiner, I.A.Lorimer, C.D.James, S.J.Russel. Rescue and propagation of fully retargeted oncolytic measles virus. Nat Biotechnol 2005; 23:209-214; PMID:15685166; http://dx.doi.org/10.1038/nbt1060
98. Y.Jing, C.Tong, J.Zhang, T.Nakamura, I.Iankov, S.J.Russel, J.R.Merchan. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor. Cancer Res 2009; 69:1459-1468; PMID:19208845; http://dx.doi.org/10.1158/0008-5472.CAN-08-2628
99. G.Ungerechts, C.Springfeld, M.E.Frenzke, J.Lampe, P.B.Johnston, W.B.Parker, E.J.Sorscher, R.Cattaneo. Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res 2007; 67:10939-47; PMID:18006839; http://dx.doi.org/10.1158/0008-5472.CAN-07-1252
100. C.Allen, G.Paraskevakou, I.Iankov, C.Giannini, M.Schroeder, J.Sarkaria, R.K.Puri, S.J.Russell, E.Galanis. Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. Mol Ther 2008; 16:1556-64; PMID:18665158; http://dx.doi.org/10.1038/mt.2008.152
101. G.Paraskevakou, C.Allen, T.Nakamura, P.Zollman, C.D.James, K.W.Peng, M.Schroeder, S.J.Russel, E.Galanis. Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas; Mol Ther 2007; 15:677-86; PMID:17299404
102. Y.Nakatsu, M.Takeda, M.Kidokoro, M.Kohara, Y.Yanagi. Rescue system for measles virus from cloned cDNA driven by vaccinia virus Lister vaccine strain. J Virolog Methods 2006; 137:152-155; PMID:NOT_FOUND; http://dx.doi.org/10.1016/j.jviromet.2006.05.029
103. H.T.Ong, T.R.Trejo, L.D.Pharm, A.L.Oberg, S.J.Russel, K.W.Peng. Intravascularly administred RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo. Mol Ther 2009. 17:1012-21; PMID:19277014; http://dx.doi.org/10.1038/mt.2009.39
104. K.Hasegawa, T.Nakamura, M.Harvey, Y.Ikeda, A.Oberg, M.Figini, S.Canevari, L.C.Hartmann, K.-W.Peng. The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res 2006; 12:6170-8; PMID:17062694; http://dx.doi.org/10.1158/1078-0432.CCR-06-0992
105. W.J.Bellini, P.A.Rota. Genetic diversity of wild-type measles viruses: implications for global measles elimination programs. Emerg Infect Dis 1998; 4:29-35; PMID:9452396; http://dx.doi.org/10.3201/eid0401.980105
106. M.C.Knuchel, R.R.Marty, T.N.Azzouz Morin, O.Iter, A.Zuniga, H.Y.Naim. Relevance of pre-existing measles immunity prior immunization with a recombinant measles virus vector. Hum Vaccines Immunother 2013; 9:599-606; PMID:23324399; http://dx.doi.org/10.4161/hv.23241
107. B.Rager-Zisman, E.Bazarsky, A.Skibin, S.Chamney, I.Belmaker, I.Shai, E.Kordysh, D.E.Griffin. The effect of measles-mumps-rubella (MMR) immunization on the immune responses of previously immunized primary school children. Vaccine 2003; 21:2580-2588; PMID:12744894; http://dx.doi.org/10.1016/S0264-410X(03)00053-7
108. R.M.Wong-Chew, J.A.Beeler, S.Audet, J.I.Santos. Cellular and humoral immune responses to measles in immune adults re-immunized with measles vaccine. J Med Virol 2003; 70:276-280; PMID:12696117; http://dx.doi.org/10.1002/jmv.10390
109. H.Gans, R.DeHovitz, B.Forghani, J.Beeler, Y.Maldonado, A.M.Arvin. Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of live. Vaccine 2003; 3398-305; PMID:12850348; http://dx.doi.org/10.1016/S0264-410X(03)00341-4
110. M.Liniger, A.Zuniga, A.Tamin, T.N.Azzouz-Morin, M.Knuchel, R.Marty, M.Wiegand, S.Weibel, D.Kelvin, P.A.Rota, H.Y.Naim. Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles virus. Vaccine 2008; 26:2164-74; PMID:18346823
111. N.Low, S.Kraemer, M.Schneider, A.M.H.Restrepo. Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis. Vaccine 2008; 26:383-98; PMID:18082295; http://dx.doi.org/10.1016/j.vaccine.2007.11.010
112. S.A.Harper, K.Fukuda, N.J.Cox, C.B.Bridges, Advisory Committee on Immunization Practices. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the advisory committee on influenza practices (ACIP). MMWR Recomm Rep 2003; 52:1-8; PMID:AMBIGUOUS
113. E.K.Mader, Y.Maeyama, Y.Lin, G.W.Butler, H.M.Russel, E.Galanis, S.J.Russel, A.B.Dietz, K.W.Peng. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res 2009; 15:7246-55; PMID:19934299; http://dx.doi.org/10.1158/1078-0432.CCR-09-1292
114. E.A.Schenk-Braat, M.M.van Mierlo, G.Wagemaker, C.H.Bangma, L.C.Kaptein. An inventory of shedding data from clinical gene therapy trials. J Gene Med 2007; 9:910-21; PMID:17880045; http://dx.doi.org/10.1002/jgm.1096
115. M.Ludlow, R.D.de Vries, K.Lemon, S.McQuaid, E.Millar, G.van Amerongen, S.Yuksel, R.J.Verburgh, A.D.M.E.Osterhaus, R.L.de Swart, W.P.Duprex. Infection of lymphoid tissues in the macaque upper respiratory tract contributes to the emergence of transmissible measles virus. J Gen Virol 2013; 94, 1933-44; PMID:23784446; http://dx.doi.org/10.1099/vir.0.054650-0
116. I.Gresser, S.L.Katz. Isolation of measles virus from urine. N Engl J Med 1960; 263:452-4; PMID:13829216; http://dx.doi.org/10.1056/NEJM196009012630907
117. W.-H.Lin, R.D.Kouyos, R.J.Adams, B.T.Grenfell, D.E.Griffin. Prolonged persistence of measles virus RNA is characteristic of primary infection dynamics. PNAS 2012; 109:14989-14994; PMID:22872860; http://dx.doi.org/10.1073/pnas.1211138109
118. L.Rennick, R.D.de Vries, T.J.Carsillo, K.Lemon, G.van Amerongen, M.Ludlow, D.T.Nguyen, S.Yuksel, R.J.Verburgh, P.Haddock, S.McQuaid, W.P.Duprex, R.L.de Swart. Live-attenuated measles virus vaccine targets dendritic cells and macrophages in muscle of nonhuman primates. J Virol 2015; 89:2192-2200; PMID:25473055; http://dx.doi.org/10.1128/JVI.02924-14
119. P.A.Rota, A.S.Khan, E.Durigon, T.Yuran, Y.S.Villamarzo, W.J.Bellini. Detection of measles virus RNA in urine specimens from vaccine recipients. J Clin Microbiol 1995; 33:2485-8; PMID:7494055.
120. F.Morfin, A.Beguin, B.Lina, D.Thouvenot. Detection of measles vaccine in the throat of a vaccinated child. Vaccine 2002; 20:1541-3; PMID:11858860; http://dx.doi.org/10.1016/S0264-410X(01)00495-9
121. Vergison A, Lina B, Van Beers D., Van Ranst M, Stévart O, Lepage P, et al., editors. Symptomatic post vaccinal excretion of Measles in the nasopharynx: a report of nine cases. Proceedings of the 44th Annual Meeting of the Infectious Diseases Society of America (IDSA), 2006 Oct 12-15. Toronto, ON; Poster session: Pediatrics I, P605.
122. K.W.Peng, M.Frenzke, R.Myers, D.Soeffker, M.Harvey, S.Greiner, E.Galanis, R.Cattaneo, M.J.Fderspiel, S.J.Russel. Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic mice. Hum Gene Ther 2003; 14:1565-77; PMID:14577918; http://dx.doi.org/10.1089/104303403322495070
123. H.Kambara, Y.Saeki, E.A.Chiocca. Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus. Cancer Res 2005; 65:11255-8; PMID:16357128; http://dx.doi.org/10.1158/0008-5472.CAN-05-2278